Zanubrutinib for CLL: Safety & Efficacy
- Mohit Narang, indicates a growing trend among oncologists to prescribe zanubrutinib (Brukinsa) rather than ibrutinib (Imbruvica) for patients with chronic lymphocytic leukemia (CLL).
- Narang noted that while ibrutinib, a first-generation Bruton tyrosine kinase (BTK) inhibitor, has proven effective, long-term use can lead to adverse effects like atrial fibrillation (AFib) and stroke.
- According to Narang, his practice is now prescribing zanubrutinib (Brukinsa) for all new CLL patients requiring a BTK inhibitor.
Zanubrutinib is emerging as the preferred treatment for CLL over ibrutinib, thanks to its superior safety profile. Discover how oncologists are prioritizing this second-generation BTK inhibitor, Brukinsa, to minimize cardiovascular risks and improve patient outcomes. Studies show zanubrutinib’s reduced incidence of side effects like atrial fibrillation and stroke makes it a crucial advancement in managing chronic lymphocytic leukemia, particularly for patients with comorbidities. News Directory 3 reports on the shift in treatment strategies, offering insights into the proactive measures practitioners are taking. Learn why zanubrutinib is becoming the standard and how its streamlined approach is benefiting patients. Discover what’s next in CLL treatment strategies.
Zanubrutinib Preferred for CLL Treatment Due to Safety Profile
Updated June 19, 2025
Maryland Oncology hematology managing partner, Dr. Mohit Narang, indicates a growing trend among oncologists to prescribe zanubrutinib (Brukinsa) rather than ibrutinib (Imbruvica) for patients with chronic lymphocytic leukemia (CLL). This shift is largely due to zanubrutinib’s enhanced safety and lower incidence of cardiovascular side effects.
Narang noted that while ibrutinib, a first-generation Bruton tyrosine kinase (BTK) inhibitor, has proven effective, long-term use can lead to adverse effects like atrial fibrillation (AFib) and stroke. These risks are amplified in patients with existing conditions such as hypertension or obesity. Reducing cardiovascular risks is particularly crucial for CLL patients with comorbidities like diabetes, obesity, or chronic obstructive pulmonary disease (COPD), Narang said.
According to Narang, his practice is now prescribing zanubrutinib (Brukinsa) for all new CLL patients requiring a BTK inhibitor. Patients previously treated by other partners are being switched to zanubrutinib, especially those who have experienced weight gain, uncontrolled or controlled hypertension, or COPD after prolonged ibrutinib use.The goal, Narang said, is to proactively prevent potential health issues.
The one big reason is if we have a better product and,as a second-generation drug with low side effects,we have a reason to move from the first generation to the second generation,” Narang said.
Narang also cited the practical benefits of focusing on a single CLL treatment within his practice. With a large patient base, standardizing on one drug simplifies the approval process and enhances familiarity among advanced practice providers.This streamlined approach, combined with the improved safety profile of zanubrutinib, makes it the preferred choice for managing CLL and minimizing cardiovascular risks.
What’s next
The increasing adoption of zanubrutinib highlights a growing emphasis on patient safety and cardiovascular health in CLL treatment. as more data emerges, expect further refinement in treatment strategies, prioritizing therapies that minimize long-term risks and improve overall patient outcomes in chronic lymphocytic leukemia.